HighField Biopharmaceuticals to Present Preclinical Data of HFG1, a Unique mRNA-based GLP-1R Agonist, for Treatment of Diabetes, at ADA’s 84th Scientific Sessions
Filing of a U.S. IND for HFG1 is scheduled for Q3/2024 HANGZHOU, China--(BUSINESS WIRE)--HighField Biopharmaceuticals,…